#USA #San Francisco #Hagens Berman #Aardvark Therapeutics #ARD-101

Aardvark Therapeutics Class Action Alert

Aardvark Therapeutics, Inc. (NASDAQ: AARD) is currently under scrutiny as a class action lawsuit looms for its investors. Hagens Berman Sobol Shapiro LLP, a well-known shareholder rights law firm, has issued a call to those who invested and faced substantial losses between the company's initial public offering (IPO) on February 13, 2025, and May 14, 2026, the latest update reveals.

Background of the Lawsuit

The allegations center on the drug ARD-101, developed for treating hyperphagia in patients with Prader-Willi Syndrome (PWS). The complaint claims that Aardvark Therapeutics misrepresented ARD-101’s safety and efficacy. There are serious claims that the company made statements about the drug's safety that were misleading, which significantly influenced investor decisions.

Key allegations include:

• - Aardvark misled investors about the safety profile of ARD-101, indicating it was safer than proved to be true.
• - During trials, unexpected cardiac observations occurred, challenging the drug's viability at therapeutic doses.
• - As a result of these oversights, the company’s market prospects were overstated, particularly in relation to their Phase 3 clinical trials.

These claims are compounded by a concerning revelation. On February 27, 2026, Aardvark announced a voluntary pause in its Phase 3 HERO trial due to adverse cardiac observations detected during safety evaluations. This news resulted in a drastic decline of over 56% in the company's stock price. Things worsened with the FDA imposing a clinical hold on the drug on May 14, 2026, leading to a further 32.1% drop in stock prices.

Importance of the Claim

For investors seeking to recover their losses, the deadline to file a lead plaintiff motion is October 13, 2026. As a potential lead plaintiff, individuals can assert their right to represent the class impacted by Aardvark’s alleged misleading conduct. The law firm emphasizes the importance of this timing, encouraging affected shareholders to reach out and discuss their legal options.

How Affected Investors Can Proceed

If you believe you have been significantly impacted by these developments related to Aardvark’s stock, you should not delay in contacting Hagens Berman. Their team is prepared to assist potential class members and analyze prospects for recovery options. Investors can reach them via email at [email protected] or by calling 844-916-0895.

Additionally, whistleblowers with insider knowledge relevant to the case may benefit from providing such information, which could also lead to substantial rewards under the SEC Whistleblower program.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is a prominent firm in plaintiffs' rights litigation, known for advocating accountability in corporate conduct. Their efforts have previously secured over $2.9 billion for clients. As they continue the investigation into Aardvark Therapeutics, they offer transparency and guidance to those embroiled in this matter.

For those monitoring this unfolding situation, further updates and relevant details about the claims can also be found on their official website at hbsslaw.com/aard. It's essential for investors to stay informed and consider taking action before the deadline.

Conclusion
In summary, Aardvark Therapeutics faces significant legal challenges while its investors grapple with the implications of these allegations. The opportunity to lead a class action is available but time-sensitive, therefore, affected parties should act swiftly to secure their rights and potential recoveries in this case.